跳转至内容
Merck
CN

M4659

米力农

≥97% (TLC), powder, phosphodiesterase type III inhibitor

别名:

1,6-二氢-2-甲基-6-氧-（3,4′-联吡啶）-5-甲腈

登录 查看组织和合同定价。

选择尺寸

关于此项目

经验公式（希尔记法）:
C12H9N3O
化学文摘社编号:
78415-72-2
分子量:
211.22
NACRES:
NA.77
PubChem Substance ID:
24278060
UNSPSC Code:
41106305
EC Number:
278-903-6
MDL number:
MFCD00133539

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

米力农, ≥97% (TLC), powder

InChI key

PZRHRDRVRGEVNW-UHFFFAOYSA-N

InChI

1S/C12H9N3O/c1-8-11(9-2-4-14-5-3-9)6-10(7-13)12(16)15-8/h2-6H,1H3,(H,15,16)

SMILES string

CC1=C(C=C(C#N)C(=O)N1)c2ccncc2

assay

≥97% (TLC)

form

powder

color

off-white

solubility

DMSO: >10 mg/mL, H2O: insoluble

originator

Sanofi Aventis

storage temp.

2-8°C

Quality Level

200

Gene Information

human ... PDE3A(5139), PDE3B(5140), PDE4B(5142), PDE5A(8654), PTPRA(5786)
rat ... Pde3a(50678)

正在寻找类似产品? 访问 产品对比指南

相关类别

Biochem/physiol Actions

磷酸二酯酶 Ⅲ 型抑制剂；cAMP 特异性、cGMP 抑制性；强心、正性肌力血管扩张剂。

Features and Benefits

该化合物是受体分类及信号转导手册上磷酸二酯酶页面上的特色化合物。想要浏览手册的其他页面， 请单击此处。
该化合物是环核苷酸研究推荐产品。点击此处 ，查看更多环核苷酸精选产品。想要了解有关生物活性小分子在其他研究领域应用的更多信息，请访问 sigma.com/discover-bsm。
该化合物是由 Sanofi Aventis开发。浏览其他由制药公司开发的化合物以及批准药物/候选药物清单， 请单击此处。

pictograms

Skull and crossbones
GHS06

signalword

Danger

hcodes

H301

Hazard Classifications

Acute Tox. 3 Oral

存储类别

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Faceshields, Gloves, type P2 (EN 143) respirator cartridges

法规信息

新产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
0000404433
0000404433
0000317536
0000317536
0000246559

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Maria Otilia Bianchi et al.
Shock (Augusta, Ga.), 44(2), 115-120 (2015-04-22)
Despite the advancement in the postoperative care of neonates with congenital heart disease (CHD), there is little information on preoperative management of systemic and regional hemodynamics, which may be related to outcomes. We aimed to determine the preoperative effect of
R Krams et al.
American heart journal, 121(6 Pt 2), 1951-1955 (1991-06-01)
Bipyridine derivatives have recently been introduced as a new class of inodilator drugs in the intravenous therapy of heart failure. A member of this class is milrinone, which improves the inotropic state and reduces ventricular afterload, leading to improved hemodynamics.
Jerrold H Levy et al.
The Annals of thoracic surgery, 73(1), 325-330 (2002-02-09)
Phosphodiesterase inhibitors including milrinone produce positive inotropic effects by slowing the hydrolysis of cyclic adenosine monophosphate in the myocardium. With a loading dose of 50 microg/kg followed by an infusion of 0.5 microg x kg(-1) x min(-1), milrinone increases stroke
Baozeng Xu et al.
Developmental biology, 385(2), 242-252 (2013-11-20)
The oocyte becomes competent for embryonic development by involving mutual communication with cumulus cells (CCs) during folliculogenesis. How this communication takes place under physiological conditions is not fully understood. Current study examined oocyte-CCs communication in the XY sex-revered female mouse.
Dirk Bassler et al.
The Cochrane database of systematic reviews, (11)(11), CD007802-CD007802 (2010-11-12)
Persistent pulmonary hypertension of the newborn (PPHN) is a clinical syndrome characterized by suboptimal oxygenation as a result of sustained elevation in pulmonary vascular resistance after birth. Currently, the therapeutic mainstay for PPHN is optimal lung inflation and selective vasodilatation
查看所有相关文献

商品

Discover Bioactive Molecules for Nucleotides

Cyclic nucleotides like cAMP modulate cell function via PKA activation and ion channels.

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持